Loading...
NEXI logo

NexImmune, Inc.OTCPK:NEXI Stock Report

Market Cap US$139.0
Share Price
n/a
1Y0%
7D0%
1D0%
Portfolio Value
​
View

NexImmune, Inc.

OTCPK:NEXI Stock Report

Market Cap: US$139.0

NexImmune (NEXI) Stock Overview

A clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. More details

NEXI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($139)

Latest financial reports are more than a year old


NEXI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW496,346 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
496,346 investors already sharing narratives
View all narratives

NexImmune, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NexImmune
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$2.17
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change0%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Sep 07

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Neximmune GAAP EPS of -$0.69 misses by $0.01

Neximmune press release (NASDAQ:NEXI): Q2 GAAP EPS of -$0.69 misses by $0.01. Shares +3.2% AH. Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22 Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22 Company is prioritizing resources to support Company’s lead product candidates, NEXI-001 and NEXI-003
Seeking Alpha • Jul 14

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune (NASDAQ:NEXI) stock jumped 23% postmarket on Thursday after the firm received investigational new drug clearance by FDA for its first cellular therapy candidate for solid tumors. NEXI-003, an autologous antigen-specific T cell product, is being developed for patients with relapsed or refractory HPV-related cancers. The IND clearance allows NEXI to begin phase 1 clinical trial to evaluate NEXI-003 for treatment of HPV-related cancers. The proposed study is a 2-part, multicenter, open-label, dose-finding, first-in-human study to evaluate safety and clinical activity of NEXI-003. "The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24-36 patients overall," NEXI said in a statement. After initial data and recommended phase 2 dose has been confirmed, NEXI plans to expand the NEXI-003 development program to include other HPV-related cancers and evaluate potential SOC combination options. NEXI stock has fallen 69% YTD.
Seeking Alpha • May 31

NexImmune: Selling For Under Cash Value

Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress. In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective and less toxic. Trading at a discount to cash, but with only enough to get NexImmune to 2Q23 (covering two data updates in 2H22), the recent purchases by three insiders merited further investigation. A full investment analysis follows in the paragraphs below.
Analysis Article • May 26

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 19

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

NEXIUS BiotechsUS Market
7D0%4.1%1.6%
1Y0%41.1%18.6%

Return vs Industry: NEXI underperformed the US Biotechs industry which returned 41.1% over the past year.

Return vs Market: NEXI underperformed the US Market which returned 18.6% over the past year.

Price Volatility

Is NEXI's price volatile compared to industry and market?
NEXI volatility
NEXI Average Weekly Movementn/a
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: NEXI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NEXI's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/an/awww.neximmune.com

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.

NexImmune, Inc. Fundamentals Summary

How do NexImmune's earnings and revenue compare to its market cap?
NEXI fundamental statistics
Market capUS$139.00
Earnings (TTM)-US$20.62m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is NEXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEXI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$20.62m
Earnings-US$20.62m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NEXI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 00:54
End of Day Share Price 2026/06/25 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NexImmune, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kaveri PohlmanBTIG
Alethia YoungCantor Fitzgerald & Co.